GBA Real-world Research Forum to explore opportunities in research and applications
The Measure of using Hong Kong and Macau registered drugs and medical devices in GBA gives the region a competitive edge in developing real-world data research and applications. Aiming to develop an ecosystem for RWD, the HKAPI and the R&D-based Pharmaceutical Association Committee under the China Association of Enterprises with Foreign Investment (RDPAC) co-organized “2024 GBA Real-world Research Forum” on 22 October, at the Guangzhou International Bio-Island.
The forum invited representatives from Mainland China and Hong Kong Governments, including the Guangdong Provincial Medical Products Administration (GDMPA), the Health Commission of Guangdong Province, the Guangzhou Municipal Industry and Information Technology Bureau, Guangzhou Municipal Government Affairs Data Administration, HKSAR Health Bureau and Department of Health etc. It also welcomed representatives from multinational pharmaceutical companies and academia.
Guest speakers highlighted the importance of RWD in the healthcare sector and agreed that RWD is a strategic direction for the GBA. It is also important to ensure data quality and establish a standard for data collection and access.
Keynote speakers include (in the sequence of appearance):
- 陳平雁教授（南方醫科大學）
- 黃志基教授（香港大學藥理及藥劑學系、倫敦大學學院藥學院名譽教授）
- 周文浩院長（廣州醫科大學附屬婦女兒童醫療中心）
- 金春林所長（上海市衞生和健康發展研究中心）
- 蔣 杰院長（大灣區真實世界研究院）
- 朱亞莉女士（中保科聯（廣州）技術有限責任公司業務負責人）
- 張正龍博士（香港大學藥理及藥劑學系副教授）
- 谷成明博士（賽諾菲大中華區醫學部負責人）
- 余洪華主任（廣東省人民醫院眼科主任）
- 鍾 敏博士（美敦力副總裁，臨床研究和醫學科學）
- 楊 忠院長（上海國際人類表型組研究院執行院長、復旦大學表型組研究院常務副院長、粵港澳大灣區精准醫學研究院副院長）
- 汪 敏博士（因美納大中華區醫學事務部負責人）
During the closed-door luncheon, guests explored further on how to leverage the unique advantages of GBA to develop RWD. Professor Ian Wong from the Department of Pharmacology and Pharmacy at HKU suggested establishing a data platform to collect medical data in GBA. Data are accessible across GBA cities.
Mr Nicholas Teo, Board member of the HKAPI, represented the Association to deliver closing remarks. He pointed out that Hong Kong has an efficient drug registration system and extensive experience in real-world data research. Along with the Hospital Authority’s medical records, Hong Kong data could serve as a foundation of the GBA data platform.
He hopes that this forum is just the beginning and that future collaborations will drive the development and application of real-world research in the region.
